- Home
- CAN vs CRMD Comparison
CAN vs CRMD Comparison
Compare CAN & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- CRMD
- Stock Information
- Founded
- CAN 2013
- CRMD 2006
- Country
- CAN Singapore
- CRMD United States
- Employees
- CAN N/A
- CRMD N/A
- Industry
- CAN Semiconductors
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- CRMD Health Care
- Exchange
- CAN Nasdaq
- CRMD Nasdaq
- Market Cap
- CAN 280.5M
- CRMD 279.7M
- IPO Year
- CAN 2019
- CRMD 2010
- Fundamental
- Price
- CAN $0.99
- CRMD $11.20
- Analyst Decision
- CAN Strong Buy
- CRMD Strong Buy
- Analyst Count
- CAN 4
- CRMD 5
- Target Price
- CAN $3.38
- CRMD $12.60
- AVG Volume (30 Days)
- CAN 5.2M
- CRMD 946.7K
- Earning Date
- CAN 11-26-2024
- CRMD 11-12-2024
- Dividend Yield
- CAN N/A
- CRMD N/A
- EPS Growth
- CAN N/A
- CRMD N/A
- EPS
- CAN N/A
- CRMD N/A
- Revenue
- CAN $189,341,000.00
- CRMD $806,119.00
- Revenue This Year
- CAN $24.54
- CRMD N/A
- Revenue Next Year
- CAN $43.73
- CRMD $206.77
- P/E Ratio
- CAN N/A
- CRMD N/A
- Revenue Growth
- CAN N/A
- CRMD 2107.40
- 52 Week Low
- CAN $0.72
- CRMD $2.57
- 52 Week High
- CAN $3.50
- CRMD $11.22
- Technical
- Relative Strength Index (RSI)
- CAN 50.09
- CRMD 87.53
- Support Level
- CAN $0.95
- CRMD $9.67
- Resistance Level
- CAN $1.02
- CRMD $10.66
- Average True Range (ATR)
- CAN 0.05
- CRMD 0.48
- MACD
- CAN -0.00
- CRMD 0.10
- Stochastic Oscillator
- CAN 41.96
- CRMD 99.38
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment as well as the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.